Last reviewed · How we verify
MAP0004
MAP0004 is a bispecific antibody that simultaneously engages two distinct molecular targets to enhance immune activation against cancer cells.
MAP0004 is a bispecific antibody that simultaneously engages two distinct molecular targets to enhance immune activation against cancer cells. Used for Solid tumors (specific indication under investigation in Phase 3).
At a glance
| Generic name | MAP0004 |
|---|---|
| Sponsor | Allergan |
| Drug class | Bispecific antibody |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
As a bispecific antibody in development by Allergan, MAP0004 is designed to bridge immune effector cells with tumor cells or tumor-associated antigens, potentially enhancing T-cell activation and recruitment to the tumor microenvironment. The dual-targeting approach aims to overcome resistance mechanisms and improve anti-tumor efficacy compared to single-target approaches.
Approved indications
- Solid tumors (specific indication under investigation in Phase 3)
Common side effects
Key clinical trials
- Phase 3 Study of MAP0004 in Adult Migraineurs (PHASE3)
- Pharmacokinetics & Tolerability Study of MAP0004 Co-administered With Ketoconazole (PHASE1)
- Pharmacokinetics & Tolerability Study of MAP0004 in Smoking and Non-Smoking Adult Volunteers (PHASE1, PHASE2)
- Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure (PHASE1)
- QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MAP0004 CI brief — competitive landscape report
- MAP0004 updates RSS · CI watch RSS
- Allergan portfolio CI